Rhythm Biosciences (RHY) Stock Price, News & Analysis

Company Overview

Rhythm Biosciences Limited, engages in developing and commercializing medical diagnostics technology in Australia and internationally. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$26.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RHY Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Rhythm Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Biosciences investors own include Vicarious Surgical (RBOT), Epsilon Healthcare (EPN) and BBX Minerals (BBX).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: ASX:RHY
• CIK: N/A
• Web: www.rhythmbio.com
• Phone: 61 3 8256 2880
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$6.86 million
• Net Margins: -166.77%
• Pretax Margin: N/A
• Return on Equity: -649.88%
• Return on Assets: -93.69%

Debt

• Debt-to-Equity Ratio: 18.89
• Current Ratio: 1.58
• Quick Ratio: 8.24

Sales & Book Value

• Annual Sales: A$1.69 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 248,600,000
• Free Float: N/A
• Market Cap: A$26.11 million
• Optionable: Not Optionable
• Beta: 2.65